Torben Grönnebaek
John Dalli o Andrzej Rys, Comisión Europea
Ministerio de Salud, Polonia

Ministerio de Salud, Espana

• Where are we?

  • Terkel Andersen, Presidente de Eurordis

• State of the art of services in Europe: where are the problems?

  • Dr Ségolène Aymé, Leader of the Task Force on Rare Diseases

• The German plan for rare diseases: a development in progress

  • Prof Dr. Johann Matthias Graf von der Schulenburg, Director, Forschungsstelle für Gesundheitsökonomie, Leibnitz Universität

El Valor Añadido de los Centros de Especialización

Introduction

Yann Le Cam (invitado)

Round table with:

• Prof Fons J.M. Gabreels, the Netherlands (invitado)
• Stein Are Aksnes, Directorate for Health and Social Affairs, Noruega
• Cristina Rusu, Romania

Optimizar los Fondos para las Pruebas Genéticas

Not all tests are useful. Are we wasting resources?

Bruno Dallapiccola, Istituto CSS Mendel, Italia

Cross Border genetic testing

Prof David Barton, Irlandia

Undiagnosed Rare Diseases

Milan Macek, Department of Biology and Medical Genetics, Charles University, República Checa

Mejorar el Acceso a los Medicamentos No Comercializados

EUnetHTA working group on Monitoring emerging/new technology development and prioritisation of HTA

Claudia Wild,  Ludwig Boltzman Institute of Health Technology Assessment, Vienna, Austria

The point of view of the industry

No confirmado

The point of view of a national authority

Krzysztof Landa, Director of the Department of Drug Management, National Health Fund, Poland

Mrs Maria Kaczynska
Mr John Dalli (invitado)
Mr Terkel Andersen